The mission of the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership with the United States Food and Drug Administration (FDA) is to identify, prioritize, sponsor, coordinate, and promote innovative activities — with a special interest in optimizing clinical trials — that will expedite the discovery and development of improved analgesic, anesthetic, and addiction treatments for the benefit of the public health.

ACTTION is a multi-year, multi-phase initiative that is closely aligned with the FDA's Critical Path Initiative. This public-private partnership has been designed to streamline the discovery and development process for new analgesic, anesthetic, and addiction medications and to more generally accelerate the development of treatments with improved efficacy and safety.

The key objectives of ACTTION involve initiating and supporting strategic collaborations among a broad spectrum of stakeholders — including, but not limited to, academia, the FDA and other government agencies, industry, professional organizations, patient advocacy groups, foundations, and philanthropic organizations — with the goals of sharing data and innovative thinking about the development of novel therapeutics. These strategic collaborations involve a wide range of research projects and other activities, for example, scientific workshops, consensus meetings, and in-depth analyses of clinical trial data to determine the effects of research methods on study assay sensitivity and efficiency.

ACTTION is intended to have benefits that are international in scope. To represent the bridges that ACTTION is establishing among its diverse stakeholders, this website is illustrated with watermarks of two bridges that share the distinction of connecting different continents. Directly below is the First Bosphorus Bridge in Istanbul, Turkey, which connects Europe and Asia; on the Contact Us webpage is the Leifur Eiriksson Bridge in Iceland's Reykjanes peninsula, which spans a rift valley between the North American and European continental plates.

News

April 24, 2013: New ACTTION Consortium on Peripheral Neuropathy

A new ACTTION consortium has been established as a result of an FDA public workshop on “Clinical development programs for disease-modifying agents for peripheral neuropathy” that was held on February 11-12, 2013. The CONsortium on Clinical Endpoints and Procedures for Peripheral neuropathy Trials (CONCEPPT) will be co-chaired by Dr. Roy Freeman of Harvard University. On the basis of the FDA public workshop and subsequent discussions, CONCEPPT will undertake various activities, including the development of new efficacy outcome measures for disease-modifying peripheral neuropathy trials and convening meetings and preparing consensus recommendations for clinical trial designs of disease-modifying treatments.

April 18, 2013: Pain Research Forum Article Highlighting ACTTION-American Pain Society Pain Taxonomy Initiative

An article describing the need for new approaches to classifying and diagnosing chronic pain and describing the objectives and current status of the ACTTION-American Pain Society Pain Taxonomy (AAPT) initiative has been published on the Pain Research Forum website. The Pain Research Forum provides a place for the international pain research community to engage in an open exchange of information and ideas with the ultimate goal being to foster discussion and collaboration that will speed the acquisition of new knowledge and its translation into novel treatments for pain. The article discussing AAPT is available here.

April 17, 2013: Shannon M. Smith, PhD, Appointed Assistant Director of ACTTION

ACTTION is pleased to announce that Shannon M. Smith, PhD, has been appointed Assistant Director. Shannon has chaired the ACTTION Safety and Benefit-Risk Reporting and Evaluation (SABRRE) Working Group for almost two years, and has spearheaded two ACTTION publications that have appeared in Pain and five others that are in various stages of the publication pipeline. Shannon also serves as the chair of ACTTION’s Pain-Related Outcomes Training and Evaluation for Conducting Clinical Trials (PROTECCT) Working Group – which has developed patient training materials for rating pain intensity and is now conducting a randomized study of the impact of training on the validity of pain ratings – and as the co-chair of ACTTION’s Abuse Liability Evaluation for Research, Treatment, and Training (ALERTT) Working Group. She received her BA from Wellesley College and her PhD in social psychology from the University of Rochester.